Prognostic Significance of Peripheral Blood CD8highCD57+ Lymphocytes in Bladder Carcinoma Patients After Intravesical IL-2

• Published in: Anticancer research 2011-02, Vol.31 (2), p.699-703
• Main Authors: CHARACIEJUS, Dainius, PASUKONIENE, Vita, JACOBS, John J. L, EIDUKEVICIUS, Rimantas, JANKEVICIUS, Feliksas, DOBROVOLSKIENE, Neringa, MAURICAS, Mykolas, VAN MOORSELAAR, R. Jeroen A, DEN OTTER, Willem
• Format: Article
• Language: English
• Subjects: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Biological and medical sciences; CD57 Antigens - biosynthesis; CD57 Antigens - immunology; CD8-Positive T-Lymphocytes - immunology; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Interleukin-2 - administration & dosage; Male; Medical sciences; Middle Aged; Neoplasm Recurrence, Local; Nephrology. Urinary tract diseases; Prognosis; Tumors; Tumors of the urinary system; Urinary Bladder Neoplasms - blood; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - immunology; Urinary Bladder Neoplasms - surgery; Urinary tract. Prostate gland
• ISSN: 0250-7005; 1791-7530

The objective of this study was to evaluate the recurrence-preventing effect of intravesical instillations of interleukin-2 (IL-2) in patients with non-muscle-invasive bladder carcinoma. In addition, this study aimed to determine the significance of immune parameters for recurrence-free interval. Twenty-six patients with non-muscle-invasive bladder carcinoma were treated with intravesical instillations of IL-2 (Proleukin®, Novartis, formerly Chiron) in doses of 9 × 10(6) IU on 5 consecutive days, beginning on the second day after transurethral resection (TUR) of tumours. CD8(high)CD57(+) lymphocytes in peripheral blood were determined before TUR and compared with the recurrence-free interval after treatment. The multivariate analysis showed that CD8(high)CD57(+) lymphocytes had a prognostic significance in combination with number of bladder tumours, prior recurrence rate and age of patients. Peripheral blood CD8(high)CD57(+) lymphocytes have prognostic significance for recurrence-free survival in patients with non-muscle-invasive bladder carcinoma after TUR and intravesical IL-2.